S
Stephen C. Mathai
Researcher at Johns Hopkins University School of Medicine
Publications - 228
Citations - 7906
Stephen C. Mathai is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Pulmonary hypertension & Medicine. The author has an hindex of 41, co-authored 176 publications receiving 6387 citations. Previous affiliations of Stephen C. Mathai include Johns Hopkins University & University of Barcelona.
Papers
More filters
Journal ArticleDOI
Tricuspid annular displacement predicts survival in pulmonary hypertension.
Paul R. Forfia,Micah R. Fisher,Stephen C. Mathai,Traci Housten-Harris,Anna R. Hemnes,Barry A. Borlaug,Elzbieta Chamera,Mary C. Corretti,Hunter C. Champion,Theodore P. Abraham,Reda E. Girgis,Paul M. Hassoun +11 more
TL;DR: TAPSE powerfully reflects RV function and prognosis in PAH and persisted after adjusting for other echocardiographic and hemodynamic variables and baseline treatment status.
Journal ArticleDOI
Pulmonary Capillary Wedge Pressure Augments Right Ventricular Pulsatile Loading
Ryan J. Tedford,Paul M. Hassoun,Stephen C. Mathai,Reda E. Girgis,Stuart D. Russell,David R. Thiemann,Oscar H. Cingolani,James O. Mudd,Barry A. Borlaug,Margaret M. Redfield,David J. Lederer,David A. Kass +11 more
TL;DR: Pulmonary hypertension and pulmonary fibrosis do not significantly change the hyperbolic dependence between RPA and CPA, and patient age has only minimal effects, which helps explain the difficulty of reducing total right ventricular afterload by therapies that have a modest impact on mean RPA.
Journal ArticleDOI
Clinical differences between idiopathic and scleroderma-related pulmonary hypertension
Micah R. Fisher,Stephen C. Mathai,Hunter C. Champion,Reda E. Girgis,Traci Housten-Harris,Laura K. Hummers,Jerry A. Krishnan,Fredrick M. Wigley,Paul M. Hassoun +8 more
TL;DR: There are significant clinical and survival differences between IPAH and PAH-Scl, and the presence of left heart disease, although more common in PAH, was not predictive of the higher mortality in these patients.
Journal ArticleDOI
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
Stephen C. Mathai,Laura K. Hummers,Hunter C. Champion,Fredrick M. Wigley,Ari L. Zaiman,Paul M. Hassoun,Reda E. Girgis +6 more
TL;DR: While therapy may be associated with improved survival in PAH compared with historical controls, the prognosis for patients with ILD-associated PH is particularly grim and survival in SSc complicated by PH remains poor despite currently available treatment options.
Journal ArticleDOI
The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension
TL;DR: The estimated consensus MID in the 6MWT for PAH is approximately 33 m, which has important implications for assessing treatment responses from clinical trials and metaanalyses of specific PAH therapy, and sample size calculations for future study design.